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Kynurenine 3-monooxygenase is a critical
regulator of renal ischemia–reperfusion
injury
Xiaozhong Zheng1, Ailiang Zhang1, Margaret Binnie2, Kris McGuire2, Scott P. Webster2, Jeremy Hughes1,
Sarah E. M. Howie1 and Damian J. Mole 1
Abstract
Acute kidney injury (AKI) following ischemia–reperfusion injury (IRI) has a high mortality and lacks specific therapies.
Here, we report that mice lacking kynurenine 3-monooxygenase (KMO) activity (Kmonull mice) are protected against
AKI after renal IRI. We show that KMO is highly expressed in the kidney and exerts major metabolic control over the
biologically active kynurenine metabolites 3-hydroxykynurenine, kynurenic acid, and downstream metabolites. In
experimental AKI induced by kidney IRI, Kmonull mice had preserved renal function, reduced renal tubular cell injury,
and fewer infiltrating neutrophils compared with wild-type (Kmowt) control mice. Together, these data confirm that
flux through KMO contributes to AKI after IRI, and supports the rationale for KMO inhibition as a therapeutic strategy to
protect against AKI during critical illness.
Introduction
In eukaryotes, the metabolic fate of the essential amino-
acid tryptophan is conversion via the kynurenine pathway
into a range of metabolites that includes kynurenic acid, 3-
hydroxykynurenine, and quinolinic acid. Enzymes involved
in the metabolism of tryptophan along the kynurenine
pathway are located throughout the body and brain, and
are most abundant in the liver and kidney. The conversion
of tryptophan to N-formylkynurenine (KYN) is catalyzed
by tryptophan 2,3-dioxygenase (TDO) and indoleamine
2,3-dioxygenases (IDOs). The kynurenine pathway diver-
ges at kynurenine into two distinct branches that are
regulated by kynurenine aminotransferases (KATs) and
kynurenine 3-monooxygenase (KMO), respectively
(Fig. 1). KMO is the only route of 3-hydroxykynurenine
production known to occur in humans. KMO localizes to
the outer membrane of mitochondria, and is highly
expressed in peripheral tissues, including liver and kidney1.
KMO expression in mouse kidney is localized to the
proximal tubule epithelial cells when measured by single-
cell transcriptomics2 and KMO protein in humans is
also localized to kidney tubule epithelial cells using
immunohistochemistry3. 3-Hydroxykynurenine is injur-
ious to several cell types4, causing tissue injury via oxida-
tive stress, pathological cross-linking of proteins5, and
inducing apoptotic cell death6,7. Kynurenine may also be
metabolized to kynurenic acid by KATs and to anthranilic
acid by kynureninase. Kynurenic acid is sedative8 and has
been shown to be protective against cell injury in certain
inflammatory situations9,10.
Renal ischemia–reperfusion injury (IRI) is a leading
cause of acute kidney injury (AKI). AKI, as a component
of multiple organ dysfunction syndrome (MODS), has a
high mortality and lacks specific therapies. Renal IRI may
occur as a result of primary decrease in blood flow, fol-
lowed by reperfusion, for example, during abdominal
aortic aneurysm repair or renal transplantation, or sec-
ondary to, and as part of a systemic inflammatory
response, for example, during sepsis or severe acute
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pancreatitis (AP)11. The exact mechanisms that drive AKI
in systemic inflammation and MODS are not well
understood, but are likely to stem from a combination of
hypoperfusion–reperfusion (IRI) and metabolic toxicity.
In the context of secondary AKI, in experimental rodent
models of AP-MODS, in which AKI is an important
contributor, pharmacological inhibition of KMO, and
separately, transcriptional blockade of the Kmo gene,
reduces 3-hydroxykynurenine formation and protects
against AKI12–15. However, whether Kmo gene blockade
protects against primary IRI-induced AKI is not known.
Therefore, to further elucidate the role of renal KMO in
protecting against experimental AKI, we tested whether
mice lacking functional KMO are protected from
experimental AKI induced by the direct insult of renal IRI.
Materials and methods
Ethical considerations
All experiments were performed after Research Ethics
Committee and Veterinary review at The University of
Fig. 1 Overview of the kynurenine pathway of tryptophan metabolism. 3-Hydroxykynurenine, the product of the gate-keeper enzyme
kynurenine 3-monooxygenase (KMO), and kynurenic acid, one of the other branch metabolite are highlighted
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Edinburgh, and were conducted according to the United
Kingdom Use of Animals (Scientific Procedures) Act
1986, under license PPL60/4250.
Animals
Embryonic stem cells on a C57BL/6N background were
engineered to lack KMO activity by insertion of a polyA
transcription “stop” motif before exon 5 of the Kmo gene
(Kmotm1a(KOMP)Wtsi) by the International Knockout
Mouse Project (iKOMP). These mice were backcrossed
with C57BL/6J mice to generate mice lacking KMO
activity, hereafter referred to as Kmonull mice as previously
described12. Control mice (Kmotm1c(KOMP)Wtsi/flox(ex5)),
with normal Kmo gene transcription and KMO activity
with loxP-flanked exon 5 of Kmo but no cre-recombinase
expression and therefore a wild-type phenotype, hereafter
referred to as Kmowt mice, were generated from the same
founders as the Kmonull strain. Genotyping of all mice was
performed by polymerase chain reaction (PCR) using
primers and a protocol published previously12. Male mice
only were used. Mice were 10–15 weeks old and were
housed under specific pathogen-free conditions in the
Biomedical Research Resources Facility of the University
of Edinburgh.
Experimental IRI
Experimental kidney IRI was induced as described
previously16. Briefly, mice were given a general anesthetic
using intraperitoneal ketamine and metomidate according
to local dosage guidelines. Under aseptic conditions, a
midline laparotomy and right nephrectomy were per-
formed. The left renal pedicle was identified and occluded
by atraumatic clamp for 22min. The duration of clamping
was determined by our previous experience with this
model using the same background mouse strain. Body
temperature was maintained at 35 °C using a home-
ostatically controlled blanket (Harvard Apparatus, Boston,
MA). After reperfusion, the abdominal wall was sutured
closed with 5–0 polypropylene and the skin closed with
metal clips. Anesthesia was reversed with Antisedan. Fluid
resuscitation with 1 mL of sterile 0.9% NaCl was admi-
nistered subcutaneously to the scruff after surgery. Sham-
operated mice underwent general anesthesia, laparotomy,
and unilateral nephrectomy, but no clamping of the left
renal pedicle. The animals were singly housed and
maintained in a 28 °C warm box overnight to recover from
surgery. After 24 h, mice were humanely killed under
terminal general anesthesia. Blood was collected into
tubes containing EDTA (BD Biosciences). Urine was
collected into sterile Eppendorf tubes. Whole kidneys
were cut longitudinally and either snap frozen in liquid
nitrogen for subsequent mRNA extraction or fixed in 10%
neutral buffered formalin before embedding in paraffin
for histological analysis.
Assessment of renal function
Plasma samples were prepared from whole blood by
centrifugation at 1000 × g for 5 min followed by aliquoting
of the supernatant, freezing in dry ice and storage at
−80 °C until analysis without freeze-thaw. Amylase,
albumin, alanine aminotransferase, glucose, urea, and
creatinine were analyzed by using commercial kits
(Product codes are 17632H, 17600H, 17234H, 17630H,
17629H, and 17654H, respectively. Alpha Laboratories
Ltd, Eastleigh, UK) adapted for use on a Cobas Fara
centrifugal analyzer (Roche Diagnostics Ltd, Welwyn
Garden City, UK). Specifically, creatinine was determined
using the creatininase/creatinase-specific enzymatic
method. Urinary albumin excretion was expressed as
albumin/creatinine ratio (ACR).
Histology and digital image analysis
Histological sections (4 μm) of formalin-fixed paraffin-
embedded kidney tissue were de-waxed and taken
through a decreasing series of graded alcohols to water.
Hematoxylin and eosin (H&E) staining was performed
according to standard protocols. The H&E-stained sec-
tions were scored in a blinded fashion for assessment of
tubular necrosis in the outer medulla17. Ten representa-
tive random fields at a magnification of × 200 per section
for each sample were examined. The percentage of
tubules in the corticomedullary junction that displayed
cellular necrosis and a loss of brush border were counted.
To assess the extent of apoptotic cell death induced by
IRI, we performed terminal deoxynucleotidyl transferase
dUTP-mediated nick-end labeling (TUNEL) staining on
paraffin-embedded kidney tissue sections using a com-
mercially available kit (DeadEnd fluorometric TUNEL
system; Promega, Madison, WI, USA). Briefly, formalin-
fixed sections of 4 μm thickness were deparaffinized,
hydrated, and incubated with 20 μg/mL proteinase K to
strip proteins from the nuclei. Fragmented DNA was then
identified by the incorporation of fluorescein-12-dUTP
during an incubation step with terminal deoxynucleotidyl
transferase at 37 °C for 1 h. Sections were stained by
immersing the slides in 40mL of propidium iodide solu-
tion freshly diluted to 1 μg/mL in phosphate buffered
saline for 15min. Microscopic images were acquired at ×
10 magnification by using a Leica DC350F digital camera
system equipped with Nikon Eclipse E800 Fluorescence
microscope and Image-Pro Plus image analysis software
(Media Cybernetics). Apoptotic cells (TUNEL-positive
cells) were quantitatively assessed at × 100 magnification
for 13 fields of tubular areas in a blinded manner using
ImageJ as previously described12.
We also performed cleaved caspase-3 immunohis-
tochemistry from paraffin sections to detect renal apoptosis.
Renal macrophages were identified by immunostaining for
the tissue macrophage marker F4/80. Myeloperoxidase
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(MPO)-positive cells were quantified in post-ischemic kid-
ney sections as an index of neutrophil infiltration. The
following primary antibodies were used: cleaved caspase-3
(ASP175) antibody with cat no. 9661 (Cell Signaling,
Danvers, MA, USA) at a dilution of 1:300, anti-mouse F4/80
monoclonal antibody (clone BM8) #14-4801 (eBioscience,
Hatfield, UK) at 1:100 dilution, and rabbit anti-MPO
polyclonal antibody #1224 (Merck Millipore Corporation)
at 1:1000 dilution. Visualization was with diaminobenzoate
(DAB) according to standard protocols. Type-specific con-
trol antibodies were used to distinguish background stain-
ing. Immunohistochemistry slides were scanned in their
entirety using an AxioScan.Z1 system (Zeiss microscopy
GmbH, Oberkochen, Germany) and stored as.czi files
before export as reduced-size.jpg files into ImageJ. Enu-
meration of caspase-3+, F4/80+, and MPO+ cells was done
using ImageJ as previously described12, and expressed as
positive cells per million pixels.
RNA extraction and real-time PCR
Total RNA was extracted from kidney tissue using an
RNeasy Mini kit (Qiagen). In all, 1 μg of total RNA was
used for first-strand complementary DNA (cDNA)
synthesis using a QuantiTect Reverse Transcription Kit
(Qiagen). Expression of genes was determined by real-
time PCR. Specific TaqMan primers and probes for Kmo,
kynureninase (Kynu), Kat2, 3-hydroxyanthranilic acid
oxidase (Haao), interleukin-6 (Il6), tumor necrosis factor
α (Tnfa), chemokine (C-X-C motif) ligand 1 (Cxcl1), and
ligand 2 (Cxcl2) were purchased from Life Biotechnolo-
gies. 18S ribosomal RNA was used as a reference gene.
Amplification of cDNA samples was carried out using
TaqMan® Fast Universal PCR Master Mix (AB Applied
Biosystem) under the following conditions: 1-min dena-
turation at 95 °C, 45 cycles of 15 s at 95 °C, and 30 s at
60 °C. Thermal cycling and fluorescence detection were
conducted in a StepOne real-time PCR system (Applied
Biosystems). All reactions were carried out in triplicate
and the cycle threshold (Ct) numbers of the target gene
and reference gene in each sample were obtained. The
mRNA levels of the target gene are presented as relative
quantification (RQ) values.
Liquid chromatography-tandem mass spectrometry (LC-
MS/MS) analysis of kynurenine pathway metabolites
Samples of plasma were diluted at a ratio of 2:5 in 5 mM
ammonium formate containing 0.1% trifluoracetic acid.
Protein was precipitated by the addition of ice-cold 100%
trichloroacetic acid to samples, followed by incubation for
30min at 4 °C and centrifugation to obtain the super-
natant. Serial dilutions of each metabolite were prepared
over appropriate concentration ranges to prepare a cali-
bration curve to permit quantitation. In all, 10 µL volumes
of each sample were injected onto a Waters Select HSS
XP column (30 mm× 100mm, 2.5 µm, Waters Corp,
Elstree, Herts) using a Waters Acquity UPLC auto-
sampler, coupled to an ABSciex QTRAP 5500 mass ana-
lyzer. The flow rate was 0.35 mL/min at 25 °C. Separation
was carried out using a water:methanol gradient (both
containing 0.1% formic acid). Conditions were 50:50
water:methanol to 40:60 over 60 s, 40:60 to 35:65 over
180 s, hold 35:65 for 110 s, 35:65 to 50:50 over 10 s, and
re-equilibration at 50:50 for 200 s. The total run time was
10min. The mass spectrometer was operated in positive
electrospray mode. The transitions for the protonated
analytes were kynurenine, m/z 209-192; 3-hydro-
xykynurenine, m/z 225-202; tryptophan, m/z 205-188;
kynurenic acid, m/z 190-144; and 3-hydroxyanthranilic
acid, m/z 154-136. Collision energies were 29, 15, 11, 31,
and 33 eV respectively. Data were acquired and processed
using Analyst quantitation software (ABI Sciex).
Tissue KMO enzyme activity assay
KMO enzyme activity assay in kidney tissue was
determined as follows: 50–100mg kidney tissue sample in
1 mL cold 0.32 μM sucrose solution was homogenized
and then centrifuged at 1500 rpm for 5 min. Total protein
concentration in the homogenate was determined using a
Pierce BCA protein kit and adjusted to 2mg/mL with
0.32 μM sucrose. In all, 10 μL of homogenate was added
to 90 μL of master mix containing 200 μM kynurenine,
800 μMNADP, 3 mM G-6P, 1 unit of G6PD, 4 mMMgCI,
and 2mM HEPES with pH 7.4 in a well of a 96-well
v-bottomed plate. The mix was incubated for 2 h at 37 °C
with 250 rpm on an orbital shaker. In total, 500 μL of
100% acetonitrile, 250 ng/mL d5-tryptophan was added to
each well after the incubation and the plate was cen-
trifuged at 4000 rpm for 10 min. The supernatant was
removed and dried under nitrogen at 65 °C, and then re-
suspended in 100 μL of mobile phase (30:70 methanol:
water containing 0.1% formic acids) for LC-MS analysis.
Separation was carried out on a 5 μM, 100 × 4.6 mm
Allure Biphenyl HPLC column using a methanol/water
gradient at 50 °C with a flow rate of 500 μL/min. Typical
retention times were 2.3 min for 3HK and 2.6 min for d5-
tryptophan. The product ions of 3HK (tube lens= 75) and
d5-tryptophan (internal standards, tube lens= 55) are
detected. The peak area ratio (3HK area/d5-tryptophan
area) for each sample is calculated and the amount of
3HK is determined from a standard curve of known 3HK
concentrations (50, 100, 250, 500, 750, 1000, 1500,
2000 ng/mL). 3-Hydroxykynurenine was detected using
LC-MS/MS.
Experimental design and statistical analysis
A simple 2 × 2 factorial design was used to compare
experimental IRI versus a sham procedure in Kmonull
and Kmowt mouse strains. Group sizes were determined
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by a prospective power calculation using G-power™18
using input parameters from previous IRI experiments
using the same IRI method and background mouse
strain. A detectable effect size of 0.80 with power 1-β=
0.80 and significance, α= 0.05, resulted in group sizes
of n= 6 mice per group. All data are expressed as
mean ± SEM. All data were subjected to a one-sample
Kolmogorov–Smirnov test to check whether data
adhered to a normal distribution. Normally distributed
data were analyzed by one-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparison
test. Data that did not follow a normal distribution
were analyzed by Kruskal–Wallis test. All statistical
analyses were performed using GraphPad™ Prism
version 6.0d for Macintosh (GraphPad Software, San
Diego, CA).
Results
Kmonull mice are protected against AKI after renal IRI
To determine whether absent KMO activity affected
the severity of AKI after IRI, we compared the effect of
experimental IRI in mice. Mice on a C57BL/6 back-
ground engineered to lack KMO activity by insertion of
a polyA transcription “stop” motif before exon 5 of the
Kmo gene (Kmotm1a(KOMP)Wtsi), hereafter referred to as
Kmonull mice, were generated and maintained in our
laboratory as previously described12. Control mice
(Kmotm1c(KOMP)Wtsi/flox(ex5)), with normal Kmo gene
transcription and KMO activity with loxP-flanked exon
5 of Kmo but no cre-recombinase expression and
therefore a wild-type phenotype, hereafter referred to as
Kmowt mice, were generated from the same founders as
the Kmonull strain. We have previously shown that KMO
enzyme catalytic activity in these mice closely correlates
with gene expression at mRNA level in both mouse
strains and in multiple tissues12. Kmonull mice were
protected against the effects of renal IRI, experiencing
less severe AKI, demonstrated by a lower plasma crea-
tinine and less tubular damage than Kmowt control mice
(Fig. 2). The experimental model of IRI was effective at
inducing severe AKI, because IRI caused an elevated
plasma creatinine to 190.5 ± 26.3 μmol/L at 24 h after
IRI in Kmowt mice, compared with a plasma creatinine
of 23.7 ± 5.5 μmol/L at the equivalent time after sham
operation in Kmowt mice. Kmonull mice had a lower
plasma creatinine 24 h after IRI (111.2 ± 21.3 μmol/l)
compared with the equivalent value in Kmowt control
mice. This difference was statistically significant (P <
0.05) (Fig. 2a) with a magnitude that is biologically
relevant. Renal IRI also significantly elevated the urinary
ACR to 22,999 ± 7747 mg/g at 24 h after IRI in Kmowt
mice, compared with an ACR of 174 ± 50 mg/g at the
equivalent time after sham operation in Kmowt mice
(P < 0.01, Fig. 2b and Supplementary Figures 1a and 1b).
Urinary ACR was profoundly increased after IRI both in
Kmowt and Kmonull, confirming AKI, but the magnitude
of this elevation in Kmonull is smaller than that in Kmowt
mice although this difference is not statistically
significant (P > 0.999, Fig. 2b). Because a previous
report of a different strain of KMO-deficient mice19
reported proteinuria in unstressed KMO-deficient
mice, we measured urine and plasma albumin con-
centrations (Supplementary Figure 1a and 1c). Urine
albumin concentrations were not different between
sham-operated Kmonull and Kmowt mice, and not higher
in Kmonull mice.
When histological tubular damage was assessed, Kmo-
null mice were protected from structural AKI after IRI,
congruent with the functional protection indicated by the
plasma creatinine concentrations. Kmowt mice sustained
severe tubular damage after IRI, evidenced by widespread
tubular necrosis, loss of the brush border, cast formation,
and tubular dilatation within the outer stripe of the outer
medulla (Fig. 2c). On histological examination, kidneys
from Kmonull mice showed significantly less tubular
damage after IRI compared with equivalent tissue sections
from Kmowt mice. Kidneys from sham-operated mice
from either Kmowt or Kmonull strain incurred no visible
tubular injury on histological assessment. Quantification
of tissue injury, obtained by counting necrotic tubules
expressed as a percentage of all tubules, was significantly
lower in Kmonull IRI mice (41.3 ± 4.0%) than Kmowt IRI
mice (60.8 ± 2.3%) (P < 0.01, Fig. 2d). Together, these data
clearly show that absent KMO activity in kidney tissue
leads to a less severe functional and histological pheno-
type in AKI following experimental IRI.
Tubular epithelial cell apoptosis is reduced in the kidney of
Kmonull mice following IRI
Because therapeutic KMO inhibition protects against
renal tubular cell apoptosis in AKI during experimental
AP in rats, and because the KMO product
3-hydroxykynurenine induces apoptosis of cells in vitro,
we examined the extent of tubular cell apoptosis. We
labeled and enumerated apoptotic renal tubular cells
using the TUNEL assay. There was no difference in the
baseline apoptotic cell count in renal tubules in Kmowt
and Kmonull mice. Experimental IRI was a powerful
inducer of apoptosis in renal tubular cells, causing sub-
stantial tubular epithelial cell apoptosis detectable at 24 h
after IRI (Fig. 3a). Importantly, although Kmonull mice
sustained a degree of renal tubular cell apoptosis, the
number of TUNEL-positive apoptotic renal tubular cells
was significantly lower in Kmonull mice with IRI (19.8 ±
4.5/field) than in Kmowt control mice (49.9 ± 11.6/field)
(P < 0.05, Fig. 3b). Furthermore, immunohistochemistry
using an antibody to cleaved caspase-3 corroborated the
result obtained by TUNEL staining (Figs. 3c, d).
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Fig. 2 Biochemical indices of renal function and histological assessment of renal tubule injury after ischemia–reperfusion injury (IRI) in
Kmowt and Kmonull mice. a Plasma creatinine. b Urine albumin/creatinine ratio. c Representative digital micrographs of histological sections of
formalin-fixed paraffin-embedded kidney tissue from Kmowt and Kmonull mice after IRI or sham operation, stained with haematoxylin and eosin and
visualized by light microscopy at × 200 original magnification. Low-power images are showed on the left panel. The relative image of selected area
are showed in high power on the right panel. Tubular necrosis (white arrow), loss of the brush border (black arrow), cast formation (blue arrow), and
tubular dilatation (red arrow) are indicated within the outer stripe of the renal medulla. d Enumeration of necrotic renal tubules expressed as a
percentage of all tubules. N.D not detected. For all panels, mice were subjected to unilateral nephrectomy and contralateral IRI, or sham operation,
under general anesthesia as described. Twenty-four hours after IRI or sham operation, mice were euthanased and blood, urine, and kidney sampled
for analysis. All graphs show data from individual mice (one data point per mouse), with lines showing mean ± SEM. Group sizes were n= 6
mice per group, except for panel b, where urine was only successfully obtained from n= 5 mice per group (individual data shown). Statistically
significant differences between groups were analyzed by one-way analysis of variance (ANOVA) with post hoc Tukey’s test; *P < 0.05, **P < 0.01
and ****P < 0.0001
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Fig. 3 Detection of tubular epithelial cell apoptosis in kidney tissue after ischemia–reperfusion injury (IRI). a Representative digital
micrographs of TdT-mediated dUTP nick-end labeling (TUNEL)-stained kidney sections at × 100 original magnification. Red arrows indicate TUNEL-
positive apoptotic cells. Low-power images are showed on the left panel. The relative image of selected area are showed in high power on the right
panel. b Number of TUNEL-positive cells per low-power field. c Representative digital micrographs selected from scanned caspase-3 stained entire
kidney images. Black arrows indicate caspase-3-positive cells. Low-power images are showed on the left panel. The relative image of selected area
are showed in high power on the right panel. d Cell apoptosis expressed as caspase-3-positive cells per 106 pixels. For all panels, Kmowt and Kmonull
mice were subjected to IRI or sham operation as described and euthanased 24 h afterwards. Kidneys were sampled for analysis. Apoptotic cells
were labeled by TUNEL assay and enumerated from digitally scanned micrographs using ImageJ. Apoptotic cells were also labeled by
immunohistochemistry using antibodies to cleaved caspase-3, visualized by diaminobenzoate and enumerated. All graphs show data from individual
mice (one data point per mouse), with lines showing mean ± SEM. Group sizes were n= 6 mice per group. Statistically significant differences
between groups were analyzed by one-way analysis of variance (ANOVA) with post hoc Tukey’s test; *P < 0.05 and ***P < 0.001
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KMO deletion inhibits neutrophil infiltration in the kidney
following IRI
AKI incorporates an element of acute inflammation.
Therefore, we directly measured neutrophil accumulation
in the kidney following IRI by immunohistochemical
staining for MPO and enumeration of MPO+ cells. A
clearly measurable influx of MPO+ neutrophils was
identified on sections of kidney tissue in both Kmowt and
Kmonull mice, 24 h after IRI, compared with very low
numbers of MPO+ cells in kidneys of sham-operated
animals (Fig. 4a). Using quantitative analysis, we detected
a lower number of accumulated neutrophils in the kid-
neys of Kmonull mice (25.2 ± 4.5/106 pixels) compared
with Kmowt mice after IRI (43.4 ± 7.1/106 pixels), and this
difference was statistically significant (P < 0.05, Fig. 4b).
We also examined monocyte-derived macrophage accu-
mulation after IRI by F4/80 immunohistochemistry
(Fig. 4c). There was no significant infiltrate of cells posi-
tive for the mouse monocyte marker F4/80 in the kidney
at 24 h after renal IRI in either Kmonull mice (17.0 ± 1.2/
106 pixels) or Kmowt mice (18.2 ± 2.8/106 pixels) (Fig. 4d).
Renal IRI downregulates kynurenine pathway enzyme
mRNA expression and upregulates interleukin-6 and tumor
necrosis factor-α mRNA expression
Next, we asked whether IRI affected expression of
kynurenine pathway enzymes, specifically Kmo, kynur-
eninase (Kynu), Kat2, 3-hydroxyanthranilic acid oxyge-
nase (Haao), and Quinolinate phosphoribosyltransferase
(Qprt) in kidney tissue. Using real-time PCR, we detected
a profound and statistically significant decrease in Kmo
mRNA expression in kidney tissue after IRI in Kmowt
mice compared with baseline expression levels in sham-
operated Kmowt mice. There was no detectable Kmo
mRNA expression in kidneys from Kmonull mice, in
keeping with the expected genotype and with our previous
experience with this mouse strain (Fig. 5a). Interestingly,
IRI caused a reduction in mRNA expression in both
Kmowt and Kmonull mouse strains for Kynu, Kat2, Haao,
and Qprt when compared with sham-operated mice of
both transgenic strains. There was no strain-specific dif-
ference in the expression of Kynu, Kat2, Haao, and Qprt
mRNA attributable to Kmo gene deletion in Kmonull mice
(Figs. 5b, c, d and supplementary Figure 2). The observed
reduction in kynurenine pathway enzyme mRNA
expression cannot be explained by experimental artifact,
because quantification of mRNA expression of the pro-
inflammatory cytokines interleukin-6 (IL-6) and tumor
necrosis factor-α (TNFα) in the same cDNA preparations
used for kynurenine pathway transcripts was significantly
upregulated following IRI, and equally so in Kmowt and
Kmonull mouse strains. Sham-operated mouse kidneys
from both Kmowt and Kmonull strains had very low
expression of IL-6 and TNFα mRNA. Mice subjected to
IRI demonstrated strong upregulation of IL-6 and TNFα
compared with sham-operated mice: IL-6 mRNA
expression in the IRI kidney increased 173-fold in Kmowt
mice and 97.3-fold in Kmonull mice, respectively (Fig. 5e);
TNFα mRNA expression in the IRI kidney increased
3.9-fold in Kmowt mice and 2.1-fold in Kmonull mice
(Fig. 5f). The difference in IL-6 and TNFα mRNA upre-
gulation in IRI was not statistically significant between
Kmowt mice and Kmonull mice. We also measured che-
mokine (C-X-C motif) ligand 1 (Cxcl1) and ligand 2
(Cxcl2) mRNA levels in kidney tissue because these reg-
ulate the recruitment and infiltration of polymorpho-
nuclear cells (PMN). Cxcl1 and Cxcl2 mRNA expression
in IRI kidney tissue was significantly increased in Kmowt
mice. Cxcl2 mRNA level in Kmonull mice was lower
compared with Kmowt mice after IRI; this difference was
statistically significant (P < 0.001), and congruent with the
observation of a reduced neutrophil infiltrate. However,
there was no difference between Cxcl1 mRNA levels in
IRI kidney tissue from Kmowt mice and Kmonull mice
(Figs. 5g, h). Together, these data show that renal IRI
drives a downregulation of kynurenine pathway enzyme
mRNA expression, or potentially reflects loss of tubular
cells through necrosis, independent of the functionality of
Kmo, and simultaneously upregulates pro-inflammatory
cytokine expression.
Kynurenine metabolite changes in experimental IRI in mice
The metabolic product of KMO, 3-hydroxykynurenine,
is injurious to cells and tissues. Because Kmonull mice are
unable to form 3-hydroxykynurenine and are also pro-
tected from AKI, it was important to confirm absent
3-hydroxykynurenine in plasma and kidney tissue
after IRI. Furthermore, because the biochemical
phenotype of Kmonull mice is a diversion of kynurenine
metabolism to kynurenic acid, and because we had
observed that IRI downregulates kynurenine pathway
enzyme mRNA expression, we measured kynurenine
metabolite concentrations in plasma and tissue (Fig. 6). In
sham-operated animals, we observed the plasma bio-
chemical phenotype expected of Kmonull mice, namely
reduced (or absent) 3-hydroxykynurenine levels, reduced
3-hydroxyanthranilic acid levels, an upstream backlog of
kynurenine, and a metabolic diversion of kynurenine to
kynurenic acid. Tryptophan concentrations were not dif-
ferent between sham-operated Kmowt and Kmonull mice.
After IRI, the kynurenine pathway biochemical phenotype
showed intriguing changes: plasma tryptophan was
depleted. Tryptophan concentration in Kmonull mice was
significantly lower in the IRI group (5501 ± 999 ng/mL)
than in sham-operated group (9411.0 ± 588.2 ng/mL) (P <
0.01). Tryptophan concentration in Kmowt mice was also
significantly lower in the IRI group (3232 ± 98.6 ng/mL)
than in sham-operated group (8560 ± 893.5 ng/mL)
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Fig. 4 Neutrophil infiltration and monocyte-derived macrophage accumulation in kidney tissue after ischemia–reperfusion injury (IRI). a
Representative digital micrographs selected from scanned myeloperoxidase (MPO)-stained entire kidney images. Black arrows indicate MPO+ cells.
Low-power images are showed on the left panel. The relative image of selected area are showed in high power on the right panel. b MPO+
neutrophil infiltration, expressed as MPO+ cells per 106 pixels. c Representative digital micrographs selected from scanned F4/80-stained entire
kidney images. Red arrows indicate MPO+ cells. Low-power images are showed on the left panel. The relative image of selected area are showed in
high power on the right panel. d F4/80+monocyte-derived macrophage accumulation, expressed as F4/80+ cells per 106 pixels. For all panels, Kmowt
and Kmonull mice were subjected to IRI or sham operation as described and euthanased 24 h afterwards. Kidneys were sampled for analysis.
Neutrophils and monocyte-derived macrophages were labeled by immunohistochemistry using antibodies to myeloperoxidase (MPO) and F4/80,
respectively, visualized by diaminobenzoate and enumerated. All graphs show data from individual mice (one data point per mouse), with lines
showing mean ± SEM. Group sizes were n= 6 mice per group. Statistically significant differences between groups were analyzed by one-way analysis
of variance (ANOVA) with post hoc Tukey’s test; *P < 0.05 and ****P < 0.0001
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(P < 0.001). The degree of tryptophan depletion was less
pronounced in Kmonull mice than Kmowt mice after IRI,
but this was not statistically significant between these two
mouse strains (Fig. 6a). Kynurenine concentrations were
not altered in IRI to an extent that exceeded the profound
differences at baseline between Kmowt and Kmonull mouse
strains (Fig. 6b). Experimental IRI caused an elevation in
the potentially protective molecule kynurenic acid that
was significantly further increased in Kmonull mice with
IRI (Kmonull IRI 8738.0 ± 673.6 ng/mL and Kmowt IRI
581.6 ± 72.9 ng/mL; P < 0.0001, Fig. 6c). Although IRI
induced a rise in 3-hydroxyanthranilic acid, this was
not different between Kmowt and Kmonull mouse
strains (Kmonull IRI 324.3 ± 93.6 ng/mL and Kmowt
IRI 389.0 ± 33.3 ng/mL; Figure 6d). Concentrations of
3-hydroxykynurenine were significantly increased 24 h
after IRI in Kmowt mice in plasma (IRI 53.3 ± 6.3 ng/mL
and sham 34.0 ± 6.3 ng/mL; P < 0.05, Fig. 6e), but not in
kidney tissue (Fig. 6f), and, as expected, Kmonull mice
showed extremely low levels of 3-hydroxykynurenine in
plasma and KMO activity in kidney tissue (Figs. 6e, f).
Together, these data convincingly demonstrate that 3-
hydroxykynurenine production by KMO is a significant
contributor to AKI following renal IRI, and reinforce the
concept of KMO inhibition as a protective strategy to
protect against organ dysfunction in critical illness.
Discussion
Kynurenine metabolites are generated by tryptophan
catabolism and regulate biological processes that include
host–microbiome signaling, immune cell response, and
neuronal excitability20. More recently, we and others are
focusing on the role of the kynurenine pathway in
inflammation and tissue injury. In particular, we have
focused on the pathway enzyme KMO, which plays a key
gate-keeper role in kynurenine metabolism, by deter-
mining the metabolic fate of kynurenine generated by
upstream dioxygenases. Recent genetic analysis in mice
identified Kmo as a candidate gene associated with albu-
minuria. Glomerular KMO expression is decreased in
both mouse and human kidneys in a diabetic environ-
ment19. These previous reports support a link between
KMO expression and healthy kidney function. In the
present work, we conclusively demonstrate that KMO is a
critical regulator of tissue injury in kidneys subjected to
IRI. We used a transgenic mouse strain (Kmonull mice)
that lacks KMO activity in all tissues by disruption of
transcription in exon 5 of the Kmo gene, and compared it
with Kmowt mice with normal KMO activity. The key
finding of our paper is that Kmonull mice are significantly
protected from AKI after IRI, measured by preserved
biochemical renal function and histological evidence of
protection against tubule cell necrosis and apoptosis.
Furthermore, neutrophil infiltration was reduced in
Kmonull mice with IRI, when compared with Kmowt mice
as controls.
Tryptophan metabolism through the kynurenine path-
way is most widely studied to date in relation to disorders
of the nervous system, for example, Huntington’s disease,
stress-related depression, schizophrenia, Alzheimer’s dis-
ease, and Parkinson’s disease21. In recent years, the reg-
ulation of kynurenine metabolism has been increasingly
evaluated in relation to acute tissue injury, and has
become an attractive therapeutic target in several disease
areas22. Our data here show altered kynurenine metabo-
lite levels in Kmonull mice after IRI compared with Kmowt
IRI mice. Despite showing comparable downregulated
expression of the kynurenine pathway enzymes following
experimental IRI, levels of kynurenine and kynurenic acid
were significantly higher in Kmonull mice compared with
Kmowt controls. Although such changes are characteristic
of the Kmonull phenotype, kynurenine and kynurenic acid
levels were further increased in Kmonull IRI mice com-
pared with Kmonull sham-operated mice. These metabo-
lites may contribute to protection from AKI after IRI in
Kmonull mice, particularly since kynurenic acid has
demonstrated a protective role in a number of other
inflammatory situations through its activity at glutamate
receptors. Levels of free radical-generating 3-hydro-
xyanthranalic acid were increased to a similar degree in
both mouse strains following induction of IRI suggesting
that this metabolite is not implicated in the development
of AKI. As plasma 3HK production was significantly
higher in Kmowt IRI mice than in all other conditions, it
seems likely that 3HK-mediated effects contribute to the
observed exacerbated response to IRI. This study provides
(see figure on previous page)
Fig. 5 mRNA expression of kynurenine pathway enzymes and pro-inflammatory cytokines in kidney tissue after ischemia–reperfusion
injury (IRI). a Kynurenine 3-monoxygenase, Kmo; b kynureninase, Kynu; c kynurenine aminotransferase, Kat2; d 3-hydroxyanthranilic acid oxidase,
Haao; e interleukin-6, Il6; f tumor necrosis factor α, Tnfa. g chemokine (C-X-C motif) ligand 1, Cxcl1; h chemokine (C-X-C motif) ligand 2, Cxcl2. For all
panels, Kmowt and Kmonull mice were subjected to IRI or sham operation and euthanased 24 h afterwards. Kidney tissue was sampled, snap frozen in
liquid nitrogen, and RNA subsequently extracted for analysis by real-time PCR as described. mRNA levels of the target gene were normalized to 18S
ribosomal RNA and are presented as relative quantification (RQ) values. All graphs show data from individual mice with lines showing mean ± SEM.
Group sizes were n= 6 mice per group. Statistically significant differences between groups were analyzed by one-way analysis of variance (ANOVA)
with post hoc Tukey’s test; *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001
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further evidence that metabolic flux through the kynur-
enine pathway is upregulated in systemic inflammation,
congruent with clinical observations in humans with
AP23,24, trauma25,26, undergoing coronary artery bypass
surgery27, sepsis28, and chronic renal failure29. Plasma
concentrations of 3-hydroxykynurenine correlate with the
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Fig. 6 Kynurenine pathway metabolite concentrations in plasma and kidney tissue after ischemia–reperfusion injury (IRI). a Plasma
tryptophan; b plasma kynurenine; c plasma kynurenic acid; d plasma 3-hydroxyanthranilic acid; e plasma 3-hydroxykynurenine; f kidney tissue 3-
hydroxykynurenine. For all panels, mice were subjected to unilateral nephrectomy and contralateral IRI, or sham operation, under general anesthesia.
Twenty-four hours after IRI or sham operation, mice were euthanased and blood and kidney tissue sampled for analysis. Extracts of plasma (panels
a–e) or kynurenine 3-monooxygenase (KMO) activity in kidney tissue (panel f) were analyzed by liquid chromatography-tandem mass spectrometry
(LC-MS/MS) as described. All graphs show data from individual mice (one data point per mouse), with lines showing mean ± SEM. Group sizes were n
= 6 or n= 5 (where one plasma was not obtained) mice per group. Statistically significant differences between groups were analyzed by one-way
analysis of variance (ANOVA) with post hoc Tukey’s test; *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001
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burden of inflammation, incidence of organ dysfunction
and AP severity in human24. Altered kynurenine pathway
metabolite levels observed here suggest that KMO also
plays a critical role in kidney injury, strengthening the
rationale for the use of systemic KMO inhibitors in this
indication.
Kmonull mice were generated and characterized in our
laboratory to investigate the role of 3-hyxdroxykynurenine
as an important effector of tissue injury. In Kmonull mice,
fecundity, fertility, and longevity up to 2 years of age are not
affected, from which we can infer that prolonged KMO
blockade and consequent chronic exposure to significantly
elevated concentrations of kynurenic acid and kynurenine is
well tolerated, at least in adapted mice12. Other researchers
have also independently demonstrated that the deleted Kmo
was not essential for embryonic and postnatal survival30.
Our finding that Kmonull mice do not have albuminuria at
baseline is contrary to a report from others19, but could
possibly explained by difference in C57BL/6 substrain. The
background strain used by Konstanje et al.19 was C57BL/6N
and the background strain of our mice used in this article
is C57BL/6J. Interestingly, deleting of arylformamidase
(Afmid) in mice leads to a glomerulosclerosis phenotype.
However, the Afmid mouse also has a thymidine kinase
promoter deleted and a glucose intolerance phenotype with
reduced insulin secretion and therefore is not a clean model
from which a direct inference of an effect on kynurenine
metabolism on renal function can be drawn31,32. KMO
depletion decreased plasma 3HK level and increased plasma
KA level, which may be potentially protective against renal
damage caused by IRI.
Kidney IRI is an inevitable consequence of the proce-
dure of kidney transplantation and its severity has been
correlated with an increased incidence of both acute and
chronic rejection17,33. Apoptosis of tubular epithelial cells
contributes to the development of ischemic AKI, and
injury at this site contributes to organ failure. Inhibiting
apoptosis, both before and after renal insults, will inevi-
tably improve the outcome of human AKI34. Neutrophils
and monocytes/macrophages are important contributors
to ischemic kidney injury and repair. Neutrophils attach
to the activated endothelium and accumulate in the kid-
ney both in animal models and in human AKI35. Recent
studies have shown that pro-inflammatory cytokines and
chemokines such as TNF-α, IL-6, monocyte chemoat-
tractant protein 1, and MIP-2 contribute to the develop-
ment of renal IRI36. In the present study, we report the
original finding that genetic KMO deletion provides
protection against kidney damage caused by IRI. Renal
injury was observed on histological sections of kidney
tissue from mice with IRI. They also showed an increase
in neutrophilic inflammation and increased apoptosis. All
these features of renal injury were essentially reduced in
KMO depletion mice. Additionally, we observed that the
mRNA expression of pro-inflammatory cytokines such as
TNF-α and IL-6 increased in IRI mice compared with
sham animals, which has been reported earlier in human
AP patients24. There was no significant difference about
the TNFα and IL-6 mRNA expression between Kmonull
and Kmowt IRI mice. The chemokines C-X-C motif ligand
1 (CXCL1)/keratinocyte chemoattractant (KC), C-X-C
motif ligand 2 (CXCL2)/macrophage inflammatory
protein-2 (MIP-2) have been found to contribute to the
pathology of a number of neutrophil-dependent animal
models of disease, including IRI37–39. Our study showed
that renal CXCL1 and CXCL2 mRNA expression were
upregulated in IRI Kmowt mice compared with sham-
operated control mice. Lower CXCL2 mRNA levels in
Kmonull IRI mice compared with Kmowt IRI mice are
consistent with our observation of reduced neutrophil
infiltration.
In summary, our study shows Kmonull mice had pre-
served renal function, reduced renal tubule cell injury and
apoptosis, and fewer infiltrating neutrophils compared
with Kmowt control mice. Together, these data strongly
support the translational potential of KMO inhibition as a
therapeutic strategy to protect against renal injury in
acute inflammation.
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